🇺🇸 FDA
Pipeline program

Meningococcal Polysaccharide (Serogroups A, C, W, and Y) Tetanus Toxoid Conjugate Vaccine

MEQ00074

Phase 3 mab completed

Quick answer

Meningococcal Polysaccharide (Serogroups A, C, W, and Y) Tetanus Toxoid Conjugate Vaccine for Meningococcal Infection is a Phase 3 program (mab) at Sanofi Pasteur with 1 ClinicalTrials.gov record(s).

Program details

Company
Sanofi Pasteur
Indication
Meningococcal Infection
Phase
Phase 3
Modality
mab
Status
completed

Clinical trials